Advances and Controversies in the Biology and Therapy of Acute Leukemia and Myelodysplasia

Friday, March 18, 2016 – Newport Beach, CA

7:00–7:40  
Registration and Breakfast

7:45–7:50  
Introduction
Jacob M. Rowe, MD, Co-Chairman

Session 1: Basic Biology
Moderators: Marshall A. Lichtman, MD  
Sean Morrison, PhD

7:50–8:05  
Do somatic mutations distinguish ontogeny in AML?  
Benjamin L. Ebert, MD, PhD

8:05–8:15  
Discussion

8:15–8:30  
New Cryptic Translocations in AML  
Yi Ning, MD, PhD

8:30–8:40  
Discussion

8:40–8:55  
Clonal Heterogeneity in AML  
Elli Papaemmanuil, PhD

8:55–9:05  
Discussion

9:05–9:25  
Break

Session 2: Induction and Post-Remission Therapy
Moderators: Selina Luger, MD  
Farhad Ravandi, MD

9:30–9:45  
Why are there so few randomized studies in refractory AML?  
Elihu H. Estey, MD

9:45–9:55  
Discussion

9:55–10:10  
CAR-T in AML. How close are we?  
Saar Gill, MD

10:10–10:20  
Discussion

10:20–10:35  
Why has MRD not been routinely incorporated in AML trials?  
Brent L. Wood, MD

10:35–10:45  
Discussion

10:45–11:00  
Why the stagnation in effective therapy for MDS?  
William Blum, MD

11:00–11:10  
Discussion
11:10–11:25  Is there justification for 4 cycles of consolidation therapy in AML?
Richard F. Schlenk, MD

11:25–11:35  Discussion

11:35–12:35  Lunch

Session 3: Bone Marrow Transplantation
Moderators:  Mary Horowitz, MD
Robert Soiffer, MD

12:40–12:55  Should anyone with Ph+ ALL who is MRD-negative receive a transplant in first remission?
Mark Litzow MD

12:55–1:05  Discussion

1:05–1:20  How important is KIR alloreactivity in allogeneic transplantation?
Katharine C. Hsu, MD, PhD

1:20–1:30  Discussion

1:30–1:45  Who should receive a second transplant?
Daniel J. Weisdorf, MD

1:45–1:55  Discussion

1:55–2:10  Do patients in first complete remission need consolidation before transplantation?
Frederick R. Appelbaum, MD

2:10–2:20  Discussion

2:20–2:40  Break

Session 4: Supportive Care and Perspective
Moderators:  Kenneth Kaushansky MD
Stanley Schrier, MD

2:45–3:00  What is the role of novel thrombopoietic agents in the management of acute leukemia?
David J. Kuter, MD

3:00–3:10  Discussion

Keynote Address
3:10–3:20  Introduction of Bruce Beutler, MD
Josef T. Prechal, MD

3:20–3:50  Ernest Beutler Memorial Lecture
Innate immunity and leukemia
Bruce Beutler, MD

3:50–3:55  Discussion

3:55–4:00  Concluding Remarks and Close
Martin S. Tallman, MD, Co-Chairman